Top
Wiskott Aldrich Syndrome - Healing Genes
582
post-template-default,single,single-post,postid-582,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Wiskott Aldrich Syndrome

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells


Phase 2

4 DESCRIPTION:

Doctors at the Roswell Park Cancer Institute seek participants with one of the following diseases to undergo combination treatment of chemotherapy, radiation, and donor stem cell transplant to treat bone marrow cancer.

  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Acute Leukemia in Remission
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Acute Myeloid Leukemia With Gene Mutations
  • Aplastic Anemia
  • B-Cell Non-Hodgkin Lymphoma
  • CD40 Ligand Deficiency
  • Chronic Granulomatous Disease
  • Chronic Leukemia in Remission
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Chronic Myelomonocytic Leukemia
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Congenital Amegakaryocytic Thrombocytopenia
  • Congenital Neutropenia
  • Congenital Pure Red Cell Aplasia
  • Glanzmann Thrombasthenia
  • Immunodeficiency Syndrome
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Neoplasm
  • Paroxysmal Nocturnal Hemoglobinuria
  • Plasma Cell Myeloma
  • Polycythemia Vera
  • Recurrent Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Secondary Acute Myeloid Leukemia
  • Secondary Myelodysplastic Syndrome
  • Severe Aplastic Anemia
  • Shwachman-Diamond Syndrome
  • Sickle Cell Disease
  • T-Cell Non-Hodgkin Lymphoma
  • Thalassemia
  • Waldenstrom Macroglobulinemia
  • Wiskott-Aldrich Syndrome

Participants will receive chemotherapy for 4 days, then an immunosuppressive drug for 2 days, then total body irradiation for one day before a donor stem cell transplant is infused. The patient will recover at the hospital and be followed closely for 1 year.


PATIENT MUST:

  • Be 8 years of age and older
  • Be diagnosed with one of the blood cancers being diagnosed
  • Not have an existing sibling donor or 12/12 HLA matched unrelated donor available OR treating clinician considers haploidentical transplant referable (despite sibling donor availability or 12/12 HLA matched donor availability) due to patient’s clinical status

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Participants will receive chemotherapy for 4 days
  3. Participants will receive an immunosuppressive drug for 2 days
  4. Participants will receive total body irradiation for one day before a donor stem cell transplant is infused.
  5. The patient will recover at the hospital and be followed closely for 1 year.

LOCATIONS AND CONTACTS:

The study site is Roswell Park Cancer Institute in Buffalo, NY. Map.

Contact: Sophia R. Balderman  |  716-845-6972  |  [email protected]

 

SPONSOR INFORMATION:

Roswell Park Cancer Institute

The National Cancer Institute (NCI)

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03333486

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader